Your browser is no longer supported. Please, upgrade your browser.
BNTC Benitec Biopharma Inc. weekly Stock Chart
Benitec Biopharma Inc.
Index- P/E- EPS (ttm)-0.03 Insider Own0.30% Shs Outstand290.05M Perf Week-8.10%
Market Cap11.42M Forward P/E- EPS next Y-0.05 Insider Trans0.00% Shs Float1.07M Perf Month-0.49%
Income-6.70M PEG- EPS next Q-0.01 Inst Own4.90% Short Float0.34% Perf Quarter7.50%
Sales1.00M P/S11.42 EPS this Y128.80% Inst Trans- Short Ratio0.05 Perf Half Y-6.89%
Book/sh0.05 P/B141.90 EPS next Y-25.00% ROA-37.80% Target Price- Perf Year-34.21%
Cash/sh8.57 P/C0.83 EPS next 5Y- ROE-42.00% 52W Range4.14 - 19.80 Perf YTD-7.25%
Dividend- P/FCF- EPS past 5Y17.20% ROI- 52W High-64.17% Beta2.00
Dividend %- Quick Ratio20.30 Sales past 5Y64.60% Gross Margin- 52W Low71.38% ATR0.81
Employees13 Current Ratio20.30 Sales Q/Q-83.30% Oper. Margin- RSI (14)40.48 Volatility8.54% 12.62%
OptionableNo Debt/Eq0.03 EPS Q/Q-20.30% Profit Margin- Rel Volume0.14 Prev Close7.10
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume75.14K Price7.09
Recom1.00 SMA20-10.22% SMA50-9.79% SMA200-11.37% Volume10,644 Change-0.07%
Apr-20-20Initiated Ladenburg Thalmann Buy $14
Feb-26-16Downgrade Maxim Group Buy → Hold
Dec-31-15Reiterated Maxim Group Buy $23 → $14
Sep-16-15Reiterated Maxim Group Buy $4 → $23
Jul-08-20 08:00AM  
Apr-20-20 06:49AM  
Apr-15-20 08:52AM  
Apr-14-20 09:28PM  
Mar-30-20 10:09AM  
Mar-26-20 09:44AM  
Feb-27-20 06:18PM  
Jan-31-20 08:08AM  
Nov-27-19 08:00AM  
Nov-17-19 07:02PM  
Nov-15-19 07:00AM  
Oct-31-19 08:30AM  
Sep-30-19 09:24AM  
Sep-19-19 09:15AM  
Sep-16-19 08:00AM  
Sep-15-19 09:49PM  
Jul-31-19 08:30AM  
Jul-11-19 11:34PM  
Jun-06-19 08:09AM  
May-08-19 08:01PM  
Mar-06-19 09:52PM  
Jan-29-19 09:46PM  
Dec-21-18 10:10AM  
Nov-23-18 12:01AM  
Nov-15-18 07:35AM  
Sep-19-18 08:00AM  
Jul-14-18 02:02PM  
Jul-10-18 05:15PM  
Jul-09-18 11:04AM  
Jul-08-18 08:59PM  
May-31-18 08:00AM  
May-15-18 08:00AM  
May-03-18 08:00AM  
Apr-24-18 08:00AM  
Mar-05-18 08:00AM  
Feb-22-18 08:30AM  
Jan-23-18 04:17PM  
Jan-16-18 08:00AM  
Nov-27-17 09:30AM  
Oct-18-17 07:45AM  
Sep-05-17 02:54PM  
Sep-01-17 04:00PM  
Aug-08-17 08:30AM  
Apr-05-17 07:30AM  
Apr-04-17 04:40PM  
Mar-27-17 09:30AM  
Mar-13-17 06:00AM  
Feb-16-17 08:00AM  
Feb-03-17 09:45AM  
Feb-02-17 12:05PM  
Jan-30-17 08:00AM  
Jan-18-17 09:30AM  
Jan-17-17 11:05AM  
Dec-23-16 06:00AM  
Dec-20-16 07:00AM  
Oct-24-16 07:10PM  
Sep-23-16 11:34AM  
Aug-10-16 05:00AM  
May-24-16 04:45AM  
May-17-16 05:00AM  
Apr-25-16 08:30AM  
Mar-08-16 08:16AM  
Mar-07-16 02:29PM  
Feb-26-16 07:26AM  
Feb-25-16 10:13PM  
Jan-29-16 07:36PM  
Dec-10-15 07:51PM  
Dec-08-15 05:05PM  
Dec-07-15 08:00AM  
Oct-29-15 11:13AM  
Oct-22-15 08:00AM  
Oct-19-15 07:30AM  
Oct-14-15 08:00AM  
Oct-07-15 07:00AM  
Sep-25-15 10:23AM  
Sep-24-15 10:00AM  
Sep-23-15 08:00AM  
Sep-16-15 07:30AM  
Aug-24-15 07:30AM  
Aug-05-15 02:45PM  
Benitec Biopharma, Inc., a development-stage biotechnology company, focuses on the advancement of novel genetic medicines. Its proprietary silence and replace approach combines DNA-directed RNA interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions, including oculopharyngeal muscular dystrophy (OPMD), and chronic hepatitis B. The company was founded in 1995 and is based in Hayward, California.